Back to News
Market Impact: 0.3
Silexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic Cancer
Source: Nasdaq
Healthcare & Biotech
Silexion Therapeutics dosed the first patient in its global Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The clinical-trial initiation is a positive development for the company’s oncology pipeline, though efficacy and safety results remain pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
SLXN0.72
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Some Oura IPO Investors Were Said to Push Back Citing Valuation